Answers are grounded in this paper and cite their sources.
Demonstrates enhanced immunotherapy efficacy in triple-negative breast cancer, suggesting a novel treatment approach.
: Tumor immunotherapy has emerged as a promising approach to eliminate cancer by activating host immunity but shows limited efficacy in triple-negative breast cancer (TNBC) due to its low immunogenicity and an immunosuppressive tumor microenvironment (TME). In this study, we developed a manganese-based nanoparticle, termed HLM315, via one-step self-assembly of alendronate-modified hyaluronic acid (HA-AL), the amphiphilic cationic peptide LTX-315, and Mn 2+ under weakly alkaline conditions. HLM315 actively targeted tumors and responded to the TME, releasing LTX-315 and generating Mn 2+ . LTX-315 induced immunogenic cell death (ICD) through tumor membrane disruption and release of tumor antigens and damage-associated molecular patterns (DAMPs), thereby providing an initial signal for immune activation. Meanwhile, Mn 2+ generated reactive oxygen species (ROS) and amplified the cGAS-STING signaling. Together, these mechanisms synergistically promoted type I interferon production, dendritic cells (DCs) maturation, T-cell recruitment and activation, and elicited an enhanced immunological memory. Ultimately, HLM315 systematically reshaped the TME and potently inhibited the tumor growth in TNBC orthotopic mouse model. Overall, HLM315 establishes a coordinated antitumor immune cascade and offers a promising strategy to enhance immunotherapy efficacy in TNBC.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: